NIH study revealed how immune response triggered by COVID-19 may damage the brain
On Jul. 5, 2022, the National Institutes of Health released a study that described the immune response triggered…
Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVID
On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…
Pfizer and BioNTech announced agreement with U.S. Government to provide additional doses of COVID-19 Vaccine
On Jun. 30, 2022, Pfizer and BioNTech announced a vaccine supply agreement with the U.S. government to support…
BD launched combination test for COVID-19, Influenza A/B and Respiratory Syncytial Virus
On Jun. 30, 2022, BD (Becton, Dickinson) announced that the BD MAX Respiratory Viral Panel (RVP), a new…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Disease | FDA | Life Science History | Medicine | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 Wheel of Fortune
Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…
Pfizer and BioNTech announced Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response
On Jun. 24 2022, Pfizer and BioNTech announced positive data evaluating the safety, tolerability, and immunogenicity of two…
Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…
Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and over
On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and older
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
Pfizer-BioNTech COVID-19 vaccine received FDA Emergency Use Authorization for children 6 months through 4 years of age
On Jun. 17, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration (FDA) had granted emergency…
Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccine
On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…
Roche received FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and measure viral load levels of COVID-19
On Jun. 15, 2022, Roche announced that the US Food and Drug Administration had issued Emergency Use Authorization…
Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA
On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…
Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and over
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of…
Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study
On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data…
COVID-19 | FDA | Therapeutics
Veru submitted EUA to U.S. FDA for Sabizabulin, its anti-Inflammatory drug candidate for hospitalized COVID-19 patients
On Jun. 7, 2022, Veru announced that is had submitted an emergency use authorization (EUA) application to the…
Pfizer announced investment $120 million to produce COVID-19 oral treatment in the U.S.
On Jun. 6, 2022, Pfizer further strengthened its commitment to United States manufacturing with a $120 million investment…
Serological evidence for SARS-CoV-2 in lactating cows published
On Jun. 4, 2022, researchers reported that in areas with large cattle populations and a high prevalence of…
Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
Novavax filed in the UK for expanded conditional Marketing Authorization of COVID-19 vaccination booster in adult
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…
Immune modulator drugs improved survival for people hospitalized with COVID-19
On Jun. 2, 2022, the U.S. National Institutes of Health announced that a large randomized, placebo-controlled clinical trial…
Food allergy associated with lower risk of SARS-CoV-2 infection
On Jun. 1, 2022, the U.S. National Institutes of Health announced that an NIH funded study had found…
Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
BD launched high-throughput molecular combination test for COVID-19 and influenza A/B
On May 26, 2022, BD (Becton, Dickinson) announced a new high-throughput molecular diagnostic combination test for SARS-CoV-2 and…
Pfizer-BioNTech COVID-19 vaccine demonstrated strong immune response in children 6 months to under 5 years of age following third dose
On May 25, 2022, Pfizer and BioNTech announced topline safety, immunogenicity and vaccine efficacy data from a Phase…
Novavax participated in Oxford University Com-COV3 booster trial of COVID-19 vaccines in adolescents aged 12 through 15
On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations…
Computer model predicted dominant SARS-CoV-2 variants
On May 24, 2022, scientists at the Broad Institute of MIT and Harvard and the University of Massachusetts…